Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avicanna Inc (OP: AVCNF )

0.3200 -0.0300 (-8.57%)
Streaming Delayed Price Updated: 2:39 PM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,101
Open 0.3580
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3500
Today's Range 0.3200 - 0.3580
52wk Range 0.1717 - 0.5320
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Latest Cannabis Hires And Board Changes, Here's What You Need To Know
Cannabis ancillary company EnWave Corporation (TSX-V: ENW) (FSE: E4U) announced on Thursday that it had tapped Danna Dunnage as its new vice president of global sales and business development. Dunnage... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country
Cannabinoid-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced on Thursday that through its majority-owned subsidiary Santa Marta Golden Hemp the company... 
Via Benzinga
Topics Cannabis
Exposures Cannabis

Performance

YTD
+29.29%
+29.29%
1 Month
+65.12%
+65.12%
3 Month
+39.43%
+39.43%
6 Month
+37.87%
+37.87%
1 Year
+46.45%
+46.45%

More News

Read More
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
From Virtual Investor Conferences
Via GlobeNewswire
CBD-Focused Avicanna Reports First-Ever Adjusted EBITDA Positive Quarter, 451% YoY Spike In Q1 Record Revenue
Via Benzinga
CBD Helps With This Rare Blistering Skin Disorder, New Study From Avicanna Shows Promising Results In Epidermolysis Bullosa Treatment
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabinoid-Based Products Maker Sees Triple-Digit Growth In 2023 Gross Profit, Revenue Surges 314% YoY
Via Benzinga
Topics Cannabis
Exposures Cannabis
This Company Is Bringing Medical Marijuana Telehealth To Over Half The U.S.
Via Benzinga
Topics Cannabis
Exposures Cannabis
Can Cannabis Treat Severe Forms Of Epilepsy? New Medicine Sparks Hope As Colombia's Weed Industry Goes Global
Via Benzinga
Topics Cannabis
Exposures Cannabis
CBD-Focused Avicanna Taps Into European Market Via Exclusive Pharma Supply Deal
Via Benzinga
CBD-Focused Avicanna Announces Funding Boost For Research And Development
Via Benzinga
Avicanna Inc.: Medical Marijuana Sales Reach Record 713% YoY Growth In Q3, Introduces New Platform
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For August 23, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 25, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Canadian Cannabis Producer Reports Revenue Spike And Improved Margins In Q2, But What About Net Loss?
Via Benzinga
Topics Cannabis
Exposures Cannabis
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
Via Benzinga
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
Via Benzinga
Topics Cannabis
Exposures Cannabis
This Cannabis Company Just Launched Medical Marijuana Care Platform And Finalized Important Acquisition
Via Benzinga
Avicanna Reveals The Initial Network Of Brands On Its Cannabis Care Platform
Via Benzinga
Cannabis Stock Gainers And Losers From August 16, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From July 25, 2023
Via Benzinga
Cannabis Stock Movers For August 10, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For August 8, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From August 4, 2023
Via Benzinga
Marijuana Stock Movers For July 31, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.